

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Aflibercept for treating diabetic macular oedema

Batch 35

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

One potential equality issue was raised during consultation and the scoping workshop. One stakeholder stated that if NICE did not recommend aflibercept this could be discriminatory against those who cannot afford private healthcare.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It was agreed that this could not be considered an equality issue because socioeconomic class is not a protected characteristic and any comparison with private healthcare is outside the remit of NICE.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?

No additional stakeholders have been identified, therefore no changes to the matrix have been made.

Approved by Associate Director (name): Elisabeth George...

Date: 31/07/2014